Drug Interaction Management in Critically Ill Patient
Journal of Pharmaceutical Research International,
Drug interaction in critically ill patient is very common and affecting patients Physically, Mentally and Financially. There are various measures which has been taken to minimize this burden on patient, such as books being prepared which include various drug interaction, maintain websites and database that provides information regarding drug interactions. With the use of these website and databases the drug interaction can be managed. It is common practice that side effects of drug interaction are being managed by additional drugs, the main reason behind it could be non-availability of alternative drugs or costlier alternative. These factors remain the main cause of treatment failure in majority of patients leading to prolong. The current study was performed for the duration of 12 months, from this study it was identified that 113 types of major drug interactions commonly found in total 250 prescriptions which were evaluated and managed accordingly. Suggestions being prescribed by various sites were, avoid concomitant use of drug, use alternative therapy, and monitor closely for any adverse effect. During suggestion made by the Clinical Pharmacist, for the same drug interactions it was identified that more of drug therapy adjustment can be done then provided by the online database. The parameter on which the drug interactions management are being suggested were focused on just type of drug interaction and its effect, it does not include the actual pharmacodynamic and pharmacokinetic changes in therapy. The suggestion made by the clinical pharmacist were includes drug removal, drug dosage changes, alternative therapy, alternative route of administration, change in time interval etc. From this study it was concluded that the drug interaction management can be done at various stages of treatment with proper therapy modification by the clinical pharmacist, and if done properly it will improve the overall outcome of patient health care.
- Drug interaction
- adverse drug reaction
- critical ill patients
How to Cite
Gupta M, Chincholkar AS, Wagh RJ, Maheshwari N, Siddiqui W. A study of potential drug-drug interactions among critically ill patients at a tertiary care hospital. Int J Basic Clin Pharmacol. 2016;5(4):1281-5.
Reis AM, Cassiani SH. Prevalence of potential drug interactions in patients in an intensive care unit of a university hospital in Brazil. Clinics. 2011;66(1):9-15.
M Pereira J, A Paiva J. Antimicrobial drug interactions in the critically ill patients. Current Clinical Pharmacology. 2013;8(1): 25-38.
Janković SM, Pejčić AV, Milosavljević MN, Opančina VD, Pešić NV, Nedeljković TT, Babić GM. Risk factors for potential drug-drug interactions in intensive care unit patients. Journal of Critical Care. 2018;43:1-6.
Baniasadi S, Farzanegan B, Alehashem M. Important drug classes associated with potential drug–drug interactions in critically ill patients: highlights for cardiothoracic intensivists. Annals of Intensive Care. 2015; 5(1):1-8.
Hammes JA, Pfuetzenreiter F, Silveira FD, Koenig Á, Westphal GA. Potential drug interactions prevalence in intensive care units. Revista Brasileira de Terapia Intensiva. 2008;20(4):349-54.
Uijtendaal EV, van Harssel LL, Hugenholtz GW, Kuck EM, Zwart‐van Rijkom JE, Cremer OL, Egberts TC. Analysis of potential drug‐drug interactions in medical intensive care unit patients. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2014;34(3):213-9
Smithburger PL, Kane-Gill SL, Seybert AL. Drug–drug interactions in the medical intensive care unit: an assessment of frequency, severity and the medications involved. International Journal of Pharmacy Practice. 2012;20(6):402-8.
Payne DA, Hayes PD, Jones CI, Belham P, Naylor AR, Goodall AH. Combined therapy with clopidogrel and aspirin significantly increases the bleeding time through a synergistic antiplatelet action. Journal of Vascular Surgery. 2002;35(6): 1204-9.
Tweeddale MG, Ogilvie RI. Antagonism of spironolactone-induced natriuresis by aspirin in man. New England Journal of Medicine. 1973;289(4):198-200.
Kumar S, Thakur PK, Shah SK. A prospective assessment of polypharmacy induced drug interactions with corticosteroids. Journal of Chitwan Medical College. 2016;6(1):24-9.
Favre L, Glasson PH, Riondel A, Vallotton MB. Interaction of diuretics and non-steroidal anti-inflammatory drugs in man. Clinical Science. 1983;64(4):407-15.
Epstein MM, Nelson SD, Slattery JT, Kalhorn TF, Wall RA, Wright JM. Inhibition of the metabolism of paracetamol by isoniazid. British Journal of Clinical Pharmacology. 1991;31(2):139-42.
Ding D, Liu H, Qi W, Jiang H, Li Y, Wu X, Sun H, Gross K, Salvi R. Ototoxic effects and mechanisms of loop diuretics. Journal of Otology. 2016;11(4):145-56.
Bodhankar SL, Thakurdesai PA, Maurya OP. Effects of (RS)-Ondansetron and its enantiomers on QTc interval in Rats. Pharmacologyonline. 2006;3:153-58.
Holm J, Lindh JD, Andersson ML, Mannheimer B. The effect of amiodarone on warfarin anticoagulation: A register‐based nationwide cohort study involving the Swedish population. Journal of Thrombosis and Haemostasis. 2017;15(3):446-53.
Gandhi S, Fleet JL, Bailey DG, McArthur E, Wald R, Rehman F, Garg AX. Calcium-channel blocker–clarithromycin drug interactions and acute kidney injury. Jama. 2013;310(23):2544-53.
Kirigaya Y, Shiramoto M, Ishizuka T, Uchimaru H, Irie S, Kato M, Shimizu T, Nakatsu T, Nishikawa Y, Ishizuka H. Pharmacokinetic interactions of esaxerenone with amlodipine and digoxin in healthy Japanese subjects. BMC Pharmacology and Toxicology. 2020;21(1):1-0.
Ghenge G, Pande SD, Ahmad A, Jejurkar L, Birari T. Development and characterisation of fast disintegrating tablet of amlodipine besylate using mucilage of plantago ovata as a natural superdisintegrant. International Journal of Pharm Tech Research. 2011;3(2):938-45.
Cattaneo M. Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Arteriosclerosis, Thrombosis, and Vascular Biology. 2004;24(11): 1980-7.
Wiviott SD, Antman EM. Clopidogrel resistance: a new chapter in a fast-moving story. Circulation. 2004;109(25):3064-7.
Jones CK, Peters SC, Shannon HE. Synergistic interactions between the dual serotonergic, noradrenergic reuptake inhibitor duloxetine and the non-steroidal anti-inflammatory drug ibuprofen in inflammatory pain in rodents. European Journal of Pain. 2007;11(2):208-15.
Barbash IM, Goldbourt U, Gottlieb S, Behar S, Leor J. Possible interaction between aspirin and ACE inhibitors: Update on unresolved controversy. Congestive Heart Failure. 2000;6(6):313-8.
Spaulding C, Charbonnier B, Cohen-Solal A, Juillière Y, Kromer EP, Benhamda K, Cador R, Weber S. Acute hemodynamic interaction of aspirin and ticlopidine with enalapril: Results of a double-blind, randomized comparative trial. Circulation. 1998;98(8):757-65.
Park MH. Should Aspirin Be Used With Angiotensin‐Converting Enzyme Inhibitors in Patients With Chronic Heart Failure?. Congestive Heart Failure. 2003;9(4):206-11.
Bartoli E, Arras S, Faedda R, Soggia G, Satta A, Olmeo NA. Blunting of furosemide diuresis by aspirin in man. Journal of Clinical Pharmacology. 1980;20(7):452-8.
Jhund PS, Davie AP, McMurray JJ. Aspirin inhibits the acute venodilator response to furosemide in patients with chronic heart failure. Journal of the American College of Cardiology. 2001;37(5):1234-8.
Planas R, Arroyo V, Rimola A, Perez-Ayuso RM, Rodes J. Acetylsalicylic acid suppresses the renal hemodynamic effect and reduces the diuretic action of furosemide in cirrhosis with ascites. Gastroenterology. 1983;84(2):247-52.
Ismail M, Iqbal Z, Khattak MB, Khan MI, Javaid A, Khan TM. Potential drug-drug interactions in cardiology ward of a teaching hospital. Health Med. 2012;6:1618-24.
Mountokalakis T, Rallis D, Mayopoulou-Symvoulidou D, Komninos Z. Effect of combined administration of furosemide and aspirin on urinary urate excretion in man. Klinische Wochenschrift. 1979;57(23):1299-301.
Wilson TW, McCauley FA, Wells HD. Effects of Low‐Dose Aspirin on Responses to Furosemide. The Journal of Clinical Pharmacology. 1986;26(2): 100-5.
Vigil-De Gracia P, Dominguez L, Solis A. Management of chronic hypertension during pregnancy with furosemide, amlodipine or aspirin: a pilot clinical trial. The Journal of Maternal-Fetal & Neonatal Medicine. 2014; 27(13):1291-4.
Fu JF, Ren QY, Zhang NY, Gao B, Tu YY, Fu GQ, Li DH, Zhang YS. Inhibition potential of glimepiride (gli) towards important UDP-glucuronosyltransferase (UGT) isoforms in human liver. Die Pharmazie-An International Journal of Pharmaceutical Sciences. 2012; 67(8):715-7.
Shalom A, Friedman T, Westreich M. Effect of aspirin and heparin on random skin flap survival in rats. Dermatologic Surgery. 2008; 34(6):785-90.
Bose P, Black S, Kadyrov M, Weissenborn U, Neulen J, Regan L, Huppertz B. Heparin and aspirin attenuate placental apoptosis in vitro: Implications for early pregnancy failure. American Journal of Obstetrics and Gynecology. 2005;192(1):23-30.
Jameson SS, Baker PN, Charman SC, Deehan DJ, Reed MR, Gregg PJ, Van der Meulen JH. The effect of aspirin and low-molecular-weight heparin on venous thromboembolism after knee replacement: a non-randomised comparison using National Joint Registry Data. The Journal of bone and joint surgery. British Volume. 2012;94(7): 914-8.
Hassan KA, Mudawi MM, Sulaiman MI. Pharmacodynamics drug interactions of metformin with aspirin and nifedipine. Asian Journal of Pharmaceutical Research and Health Care. 2016;8(1).
Tai CH, Hsu CN, Yang SC, Wu CK, Liang CM, Tai WC, Chuah SK, Lee CH. The impact of aspirin on Klebsiella pneumoniae liver abscess in diabetic patients. Scientific Reports. 2020;10(1):1-0.
Zanders MM, van Herk-Sukel MP, Vissers PA, Herings RM, Haak HR, Van De Poll-Franse LV. Are metformin, statin and aspirin use still associated with overall mortality among colorectal cancer patients with diabetes if adjusted for one another?. British Journal of Cancer. 2015;113(3):403-10.
Kirkby NS, Leadbeater PD, Chan MV, Nylander S, Mitchell JA, Warner TD. Antiplatelet effects of aspirin vary with level of P2Y12 receptor blockade supplied by either ticagrelor or prasugrel. Journal of Thrombosis and Haemostasis. 2011;9(10): 2103.
Gilroy DW, Perretti M. Aspirin and steroids: New mechanistic findings and avenues for drug discovery. Current Opinion in Pharmacology. 2005;5(4):405- 11.
Koomanan N, Ko Y, Yong WP, Ng R, Wong YP, Lim SW, Salim A, Chan A. Clinical Impact of Drug–Drug Interaction Between Aspirin and Prednisolone at a Cancer Center. Clinical Therapeutics. 2012;34(12): 2259-67.
Leor J, Reicher-Reiss H, Goldbourt U, Boyko V, Gottlieb S, Battler A, Behar S. Aspirin and mortality in patients treated with angiotensin-converting enzyme inhibitors: A cohort study of 11,575 patients with coronary artery disease. Journal of the American College of Cardiology. 1999;33(7): 1920-5.
Bomback AS, Kshirsagar AV, Klemmer PJ. Renal aspirin: will all patients with chronic kidney disease one day take spironolactone?. Nature Clinical Practice Nephrology. 2009;5(2):74-5.
de Lemos JA, Blazing MA, Wiviott SD, Brady WE, White HD, Fox KA, Palmisano J, Ramsey KE, Bilheimer DW, Lewis EF, Pfeffer M. Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy: Results from the A phase of the A-to-Z trial. European Heart Journal. 2004;25(19):1688-94.
Tilgner J, von Trotha KT, Gombert A, Jacobs MJ, Drechsler M, Döring Y, Soehnlein O, Grommes J. Aspirin, but not tirofiban displays protective effects in endotoxin induced lung injury. PLoS One. 2016; 11(9):e0161218.
Kim HO, Lee KE, Park HY, Lee NR, Oh BR, Chang BC, Gwak HS. Effects of torsemide on pharmacodynamics and pharmacokinetics of warfarin in humans and rats. Journal of Pharmacy and Pharmacology. 2013;65(8):1195-203.
Kothari N, Ganguly B. Potential drug-drug interactions among medications prescribed to hypertensive patients. Journal of clinical and diagnostic research: JCDR. 2014; 8(11):HC01.
Mateti UV, Rajakannan T, Nekkanti H, Rajesh V, Mallaysamy SR, Ramachandran P. Drug-drug interactions in hospitalized cardiac patients. Journal of Young Pharmacists. 2011;3(4):329-33.
Eljaaly K, Alshehri S. An updated review of interactions of statins with antibacterial and antifungal agents. J Transl Sci. 2017;3:1-4.
Abstract View: 0 times
PDF Download: 0 times